Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Zalupski on Implications of the KEYNOTE-061 Trial in Gastric Cancer

May 29th 2019

Mark M. Zalupski, MD, professor of medicine at the University of Michigan School of Medicine, discusses the clinical implications of the phase III KEYNOTE-061 trial in gastric cancer.

TAS-102 Expands Arsenal in Gastric Cancer, But Long Road Ahead for Research

May 24th 2019

Mark M. Zalupski, MD, sheds light on the current treatment landscape of advanced gastric cancer and the numerous challenges that remain.

Dr. Anthony on Spartalizumab in NETs

May 24th 2019

Lowell B. Anthony, MD, FACP, chief, Division of Medical Oncology, University of Kentucky Markey Cancer Center, discusses preliminary research with spartalizumab (PDR001) in neuroendocrine tumors (NETs).

Dr. El-Rayes on Locoregional Therapy Versus Resection in CRC

May 23rd 2019

Bassel El-Rayes, MD, chief clinical research scientist, Winship Cancer Institute of Emory University, discusses considerations for locoregional therapy versus resection in patients with colorectal cancer.

Dr. Khan on Implications of the REFLECT Trial in HCC

May 23rd 2019

Gazala N. Khan, MD, medical oncologist, Henry Ford Health System, discusses the implications of the REFLECT trial in advanced hepatocellular carcinoma (HCC).

Targeting Mesothelin May Yield Results in Hard-to-Treat Solid Tumors

May 22nd 2019

Mesothelin, a protein found on cell surfaces and in serum, has emerged as a promising target for immunotherapy-based treatment approaches for several malignancies with poor prognoses and limited treatment options. Investigating novel approaches to optimize delivery and identifying combinations of agents to synergistically improve therapeutic response will be the next steps in bringing mesothelin-targeted therapies into the clinical setting.

Meta-Analysis Sheds Light on Treatment-Related AEs for PD-1 and PD-L1 Inhibitors

May 22nd 2019

Two in 3 patients treated with PD-1 or PD-L1 inhibitors experienced at least 1 AE and 1 in 7 patients experienced at least 1 grade ≥3 AE, according to a systematic review and meta-analysis of clinical trials and study updates published through December 15, 2018.

Optimal Sequencing Next Step Following Rapid Progress in HCC

May 22nd 2019

Gazala N. Khan, MD, highlights the recent headway made in hepatocellular carcinoma and discusses the remaining challenges.

Encorafenib, Binimetinib, and Cetuximab Triplet Improves OS, ORR in BRAF+ CRC

May 21st 2019

The triplet regimen of encorafenib, binimetinib, and cetuximab led to a 48% reduction in the risk of death compared with cetuximab and irinotecan-containing regimens in patients with BRAF V600E-mutant metastatic colorectal cancer who previously received up to 2 lines of therapy, meeting both primary endpoints of the phase III BEACON CRC trial.

Dr. Musher Discusses the Role of Regorafenib in Advanced HCC

May 21st 2019

Benjamin Leon Musher, MD, associate professor of medicine, hematology and oncology, at Baylor College of Medicine, discusses the role of regorafenib in the treatment of patients with advanced hepatocellular carcinoma.

Dr. Kopetz on the Biology of Right- Versus Left-Sided CRC

May 21st 2019

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the biology of right- versus left-sided colorectal cancer.

Expert Highlights Advances With Locoregional Therapies in HCC

May 21st 2019

Emil Cohen, MD, discusses the locoregional therapies available for the treatment of patients with hepatocellular carcinoma and offers insight into optimal strategies.

Dr. Philip Discusses Research Questions With Lutathera in NETs

May 20th 2019

Philip A. Philip, MD, PhD, FRCP, professor, Department of Oncology, Barbara Ann Karmanos Cancer Institute, discusses research questions with Lutathera in the treatment of patients with neuroendocrine tumors.

Shedding Light on the Challenging Pancreatic Cancer Paradigm

May 20th 2019

Vaibhav Sahai, MBBS, sheds light on ongoing research in metastatic pancreatic cancer and discusses the role of genomic profiling in the space.

Emerging CRC Treatments Highlight Need for Biomarker Testing

May 19th 2019

With multiple biomarker-directed clinical trials for metastatic CRC expected to produce data within the next few years, experts in gastrointestinal oncology who took part in a recent OncLive Peer Exchange® program recommended that clinicians become more proactive about incorporating genomic and immune markers into their decision making.

Dr. Shields on the Standard of Care in Newly Diagnosed mCRC

May 18th 2019

Anthony Shields, MD, PhD, oncologist, Department of Oncology, Molecular Imaging and Diagnostics Program, Barbara Ann Karmanos Cancer Institute, discusses the standard of care in patients with newly diagnosed metastatic colorectal cancer (mCRC).

Navigating Complexities of Localized Pancreatic Cancer, NETs

May 17th 2019

Philip A. Philip, MD, PhD, FRCP, discusses recent studies that have impacted locally advanced pancreatic cancer treatment and shared key updates in the neuroendocrine tumors paradigm.

Dr. Khan Discusses Sequencing Strategies in Advanced HCC

May 17th 2019

Gazala N. Khan, MD, gastrointestinal medical oncologist, Henry Ford Health System, discusses sequencing strategies in advanced hepatocellular carcinoma.

Ivosidenib Improves PFS in IDH1-Mutant Cholangiocarcinoma

May 16th 2019

Ivosidenib demonstrated a statistically significant improvement in progression-free survival by independent radiology review compared with placebo in patients with IDH1-mutant previously treated cholangiocarcinoma.

Shields Sheds Light on Complex mCRC Landscape

May 16th 2019

Anthony Shields, MD, PhD, shares recent efforts being made with immunotherapy research in colorectal cancer, stressed the importance of molecular testing, and shed light on the use of liquid biopsies in the space.